Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43974   clinical trials with a EudraCT protocol, of which   7311   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-003847-31
    Sponsor's Protocol Code Number:ICT01-101
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2019-11-12
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2019-003847-31
    A.3Full title of the trial
    A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer
    A.4.1Sponsor's protocol code numberICT01-101
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorImCheck Therapeutics
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportImCheck Therapeutics, Inc.
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationImCheck Therapeutics
    B.5.2Functional name of contact pointChief Medical Officer
    B.5.3 Address:
    B.5.3.1Street Address31 Chemin Joseph Aiguier
    B.5.3.2Town/ cityMarseille
    B.5.3.3Post code13009
    B.5.3.4CountryFrance
    B.5.4Telephone number33665 94 22 11
    B.5.6E-mailkatrien.lemmens@imcheck.fr
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameICT01
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNICT01
    D.3.9.2Current sponsor codeict01
    D.3.9.3Other descriptive nameICT01
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Pembrolizumab
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Sharp & Dohme B.V.
    D.2.1.2Country which granted the Marketing AuthorisationBelgium
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePembrolizumab
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPembrolizumab
    D.3.9.1CAS number 1374853-91-4
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed/refractory solid tumors or hematological cancers
    E.1.1.1Medical condition in easily understood language
    Relapsed/refractory solid tumors or hematological cancers
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10065147
    E.1.2Term Malignant solid tumor
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10066481
    E.1.2Term Hematological malignancy
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Part 1
    Characterize the safety and tolerability of ICT01 intravenous (IV) as monotherapy, and in combination with pembrolizumab (Keytruda®) in patients with relapsed/refractory advanced solid tumors or hematologic malignancies.
    Part 2
    Characterize the preliminary anti-tumor activity of ICT01 IV as monotherapy and in combination with pembrolizumab in patients with relapsed/refractory advanced solid tumors and in combination with venetoclax (VEN; Venclyxto®, Venclexta®)/ azacitidine (AZA; Vidaza®) in with newly diagnosed acute myeloid leukemia (AML)
    E.2.2Secondary objectives of the trial
    Part 1
    1. Determine the recommended ICT01 dose(s) for use as monotherapy and in combination with pembrolizumab.
    2. Characterize the pharmacokinetics (PK) of IV ICT01 administered as monotherapy and in combination with pembrolizumab
    3. Characterize the preliminary anti-tumor activity of a range of IV doses of ICT01 as monotherapy and in combination with pembrolizumab when administered to patients with advanced-stage, relapsed/refractory solid tumors or hematologic cancers.

    Part 2
    1. Determine the recommended ICT01 dose(s) for use in combination with VEN/AZA.
    2. Characterize the overall safety and tolerability of IV ICT01 as monotherapy, and in combination with pembrolizumab or VEN/AZA
    3.Characterize the PK of IV ICT01 administered as monotherapy and in combination with pembrolizumab or VEN/AZA.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    The following criteria must be checked over the screening period and at baseline. ALL inclusion criteria must be met to include the subject in the study:
    Part1:
    1) Male or female aged ≥18 years
    2) Voluntarily signed written informed consent before performance of any study-related screening procedures
    3) Patients with histologically or cytologically confirmed diagnosis of advanced cancer including:
    a. Group A: Relapsed/refractory advanced bladder, breast, colorectal, gastric, ovarian, or prostate cancer, melanoma, or PDAC;
    b. Group B: Relapsed/refractory advanced hematologic malignancies including AML, acute lymphocytic leukemia, diffuse large B cell lymphoma, and follicular lymphoma;
    c. Group C: Relapsed/refractory advanced bladder cancer, HNSCC, melanoma, or non‑small cell lung cancer (approved indications in US and EU for pembrolizumab);
    d.Group D: persistent or recurrent advanced epithelial ovarian cancer, primary fallopian or primary peritoneal cancer, treated with at least 1 prior systemic platinum-containing regimen and that progressed within 6 months of the end of the most recent systemic platinum-containing regimen;
    e.Group E: mCRPC in patients who failed prior androgen deprivation therapy. Patients may have also failed prior taxane therapy;
    f.Group F: Newly diagnosed AML, by WHO 2022 criteria, in patients who are indicated to start treatment with VEN/AZA
    g. Group G: metastatic or unresectable melanoma with primary resistance following at least 6 weeks of prior CPI treatment for advanced disease,
    h.Group H: locally advanced or metastatic urothelial carcinoma
    i.Group I: metastatic or unresectable, recurrent HNSCC
    4) Willingness to undergo Screening, baseline, and on-study tumor biopsies or BMAs, as applicable;
    5) Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
    6) Life expectancy > 3 months as assessed by the Investigator
    7)All groups except Group F,Clinical labs:
    a. Hematology:
    - Hemoglobin ≥8.5 g/dL (equal to 5.28 mmol/L; transfusion dependent or independent);
    - All groups except Group B and F:
    • platelet count ≥75 × 109/L;
    • lymphocyte count ≥0.5 × 109/L;
    • absolute neutrophil count ≥1.0 × 109/L;
    b. Liver enzymes:
    - AST and ALT ≤2.5 × upper limit of normal (ULN) (<5 × ULN in the case of liver metastases);
    - bilirubin ≤1.5 × ULN (<2 × ULN in case of liver metastases);
    c. Renal function: serum creatinine <1.5 × ULN or creatinine clearance ≥ 50 mL/min (Cockcroft and Gault) for serum creatinine ≥1.5x ULN.
    8) Contraceptives measures:
    a.Women of childbearing potential must:
    i.have a negative pregnancy test within 1 week before first dose of study drug
    ii.use highly effective method(s) of birth control (i.e., a method with less than 1% failure rate [e.g., sterilization, hormone implants, hormone injections, some intrauterine devices, sexual abstinence, or vasectomized partner]) consistently and correctly during the study and for at least 5 months after the last dose of any study drug
    iii.agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for at least 5 months after the last dose of study
    iv.agree to no plan to breastfeed and no plan to become pregnant during the study and for at least 5 months after the last dose of any study drug.
    b.Males who are sexually active must:
    i.agree to use a condom with spermicidal foam/gel/film/cream/suppository during the study and for at least 5 months after the last dose of anystudy drug
    ii.agree to not donate sperm during the study and for at least 5 months after the last dose of any study drug
    iii.no plan to father a child during the study or within 5 months after the last dose of study drug.
    9) Women must not be breastfeeding
    10) At least 1 measurable lesion per RECIST/ RECIL or >5% bone marrow blasts;
    11)Part 1: Patients must have no available standard of care or available treatment with potential survival benefit for their disease, as determined by the treating Investigator (see inclusion criteria #13 and #14 for Groups D, E, G, H, and I and Group F, respectively).
    12)in Groups C, G, H, and I must meet the eligibility criteria in the approved package labeling of pembrolizumab and meet the following conditions:
    a. Must not be first-line patients (i.e., must meet Inclusion Criteria #11)
    b. Must not have any history or ongoing interstitial lung disease
    c. Must not have undergone prior anterior organ transplantation, including allograft stem cell transplantation

    Part 2 Groups D, E, G, H, and I: all above criteria apply with following modifications:
    13) Replaces inclusion criterion #11: Patients must have received at least one line of treatment for their cancer prior to enrolling on the study:
    14) Replaces inclusion criterion #11: Patients must be planned to start VEN/AZA as per label indication as described in inclusion criterion 3.f;
    E.4Principal exclusion criteria
    1) Any malignancy of γ9δ2 T cell origin
    2)Any anti-tumor-directed drug therapy within 28 days or 5 times the elimination half-life (whichever is shorter) before study treatment initiation (does not apply to patients receiving pembrolizumab in the combination arms);
    3)Treatment with investigational drugs within 28 days before study treatment initiation
    4) Systemic steroids at a daily dose of > 10 mg of prednisone, > 2 mg of dexamethasone or equivalent, for the last 28 days and ongoing
    5)Patients with rapidly progressing disease defined as advanced/metastatic, symptomatic, visceral spread, with a risk of life-threatening complications in the short term (e.g., during Screening Period/ treatment washout) that includes patients with massive uncontrolled effusions pleural, pericardial, peritoneal, pulmonary lymphangitis, and over 50% liver involvement
    6)Ongoing immune-mediated adverse events (imAEs) and/or adverse events (AEs) Grade ≥2 from previous therapies, except for vitiligo, stable Grade 2 neuropathy, hair loss, and stable endocrinopathies with substitutive hormone therapy;.
    7)Within 4 weeks of major surgery
    8)Documented history of active autoimmune disorders requiring systemic immunosuppressive therapy within the last 12 months
    9)Primary or secondary immune deficiency
    10)Active and uncontrolled infections requiring intravenous antibiotic or antiviral treatment
    11)Known/suspected hypersensitivity against ICT01, human or humanized IgGs, PD-1/PD-L1 blockers or their ingredients
    12)Seropositive (except after vaccination or confirmed cure for hepatitis) for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).Patients positive for HIV can be eligible if cluster of differentiation (CD)4+ T-cell counts ≥350 cells and have no history of AIDS-defining opportunistic infections in the past 12 months, as deemed appropriate by the Investigator;
    13)Clinically significant cardiac disease including heart failure (New York Heart Association, Class III or IV), pre-existing arrhythmia, uncontrolled angina pectoris, or myocardial infarction within 1 year before study entry
    14)Dementia or altered mental status that would prohibit informed consent
    15)Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study assessed by the Investigator
    16)Active drug or alcohol abuse as assessed by the Investigator
    17)Patients with uncontrolled and symptomatic brain metastases. Patient with asymptomatic brain metastases are allowed provided they are stable and off therapeutic steroids for at least 4 weeks.
    Part 2 Group F, all above apply with following additions aligned with Viale-A trial
    18)Patients with t(15;17), t(8;21), inv(16), or t(16;16) karyotypic abnormality;
    19)Patient has history of myeloproliferative neoplasm including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia with or without BCR-ABL1 translocation, or AML with BCR-ABL1 translocation;
    20)Patient has a white blood cell count >25 x 10⁹/L. In the EU and UK: hydroxyurea, and/or cytarabine (up to 1 g total) is permitted to meet this criterion. In the US: hydroxyurea, leukapheresis, or cytarabine (low dose, e.g., 20 mg twice daily) is permitted to meet this criterion.
    21)Patients with known symptomatic or uncontrolled central nervous system leukemia;
    22)Any previous or concomitant malignancy, except when the patient has completed definitive curative-intent treatment with chemotherapy and/or surgery and/or radiotherapy at least 3 months prior to enrollment. Patients having completed definitive treatment for following conditions may be eligible immediately after completion of definitive curative intent therapy, after healing of wounds, and no evidence of residual disease by examination, imaging, and/or cytology/pathology, e.g., non-melanoma skin cancers, or a carcinoma in-situ, e.g., ductal carcinoma in situ, urothelial cancer, cervical cancer, localized prostate cancer, pre-cancerous colon polyp.
    23)Patients with contraindications to VEN or AZA according to prescribing information.
    E.5 End points
    E.5.1Primary end point(s)
    Part 1:
    Incidence, severity (according to National Cancer Institute [NCI]- Common Terminology Criteria for Adverse Events [CTCAE] Version 5), and relationship to study treatment of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to discontinuation of study treatment or treatment modifications;
    • Incidence and severity (according to NCI-CTCAE Version 5) of clinical laboratory abnormalities;
    • Clinically significant findings on vital signs, electrocardiograms (ECGs), and physical examinations.
    Part 2:
    • DCR according to RECIST Version 1.1 for solid tumors (complete response [CR] + partial response [PR] + stable disease [SD]);
    • Complete remission rate (CRR) according to the European LeukemiaNet (ELN) 2022 criteria for AML (complete remission [CR] + CR with partial hematological recovery [CRh] + CR with incomplete hematological recovery [CRi] + morphologic leukemia-free state [MLFS]).
    E.5.1.1Timepoint(s) of evaluation of this end point
    On-going throughout the duration of the study
    E.5.2Secondary end point(s)
    Part 1:
    -Incidence of dose-limiting toxicities (DLTs), other safety measures, and biomarker data.
    -PK parameters of ICT01, including maximum serum drug concentration (Cmax), area under the concentration-time curve (AUC), elimination half-life (t1/2), clearance.
    -Disease control rate (DCR) and objective response rate (ORR) according to Response Evaluation Criteria In Solid Tumors (RECIST), immunotherapy RECIST (iRECIST), Response Evaluation Criteria In Lymphoma (RECIL), or as per disease-specific standards in other hematologic indications, as appropriate.

    Part 2:
    -Incidence of DLTs, other safety measures, and biomarker data.
    -Incidence, severity (according to CTCAE Version 5), and relationship of TEAEs, SAEs, and TEAEs leading to discontinuation of study treatment or treatment modifications;
    -Incidence and severity (according to CTCAE Version 5) of clinical laboratory abnormalities;
    -Clinically significant findings on vital signs, ECGs, and physical examinations.
    -PK parameters of ICT01, including Cmax, AUC, t1/2, and clearance.
    E.5.2.1Timepoint(s) of evaluation of this end point
    On-going throughout the duration of the study
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans Yes
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA20
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United Kingdom
    United States
    Belgium
    France
    Germany
    Spain
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 264
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 145
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state25
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 350
    F.4.2.2In the whole clinical trial 409
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Normal treatment
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-12-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-01-23
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA